The ribosomal protein S6 kinase 1 (S6K1) is one of the main Background: components of the mTOR/S6K signal transduction pathway, which controls cellular metabolism, autophagy, growth, and proliferation. Overexpression of S6K1 was detected in tumors of different origin including breast cancer, and correlated with the worse disease outcome. In addition, significant accumulation of S6K1 was found in the nuclei of breast carcinoma cells suggesting the implication of kinase nuclear substrates in tumor progression. However, this aspect of S6K1 functioning is still poorly understood. The main aim of the present work was to study the subcellular localization of S6K1 in breast cancer cells with the focus on cell migration.
Amendments from Version 1
In version 2 of the manuscript we have modified the abstract and conclusions to more accurately represent the obtained data. Particularly, we have removed the statement about possible phosphorylation of transcription factor TBR2 by kinase S6K1, as it was predicted only by bioinformatic analysis. However, the existence of TBR2-S6K1 protein complex was shown by coimmunoprecipitation and colocalization assays for the first time, that is why we have left this finding in the abstract.
Information about the supplier of antibodies, that were not represented in the main figures and results (against transcription factors ERG and CDX-2), has been moved to the legend of Dataset 4.
We have removed the first introductory paragraph of the Results section, because of the feedback of both reviewers. The paragraph was descriptive, and no information about results of the research was lost.
The style and language of the manuscript was greatly improved in version 2. Some accidental typographical errors were corrected in the new version.
An additional affiliation has been listed for Kateryna Shkarina who, although was a Masters student at the Educational and Scientific Center, Taras Shevchenko National University of Kyiv at the time of version 1, carried out almost all the research at The Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine.
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described as a predominantly nuclearly localized kinase. However, recent studies based on nuclear-cytoplasmic fractionation revealed its presence in the cytoplasm of the breast cancer cells and primary human fibroblasts (Kim et al., 2009; Rosner & Hengstschläger, 2011) . The most abundant isoform of S6 kinase, p70S6K1, was thought to localize predominantly in the cytoplasm, however treatment of the cells with leptomycin B (the nuclear export inhibitor) has been shown to cause its accumulation in the nucleus, leading to the conclusion that p70S6K1 may shuttle between the cytoplasm and nucleus of the cell (Panasyuk et al., 2006) . To date, there is still very little evidence about the subcellular localization of p31S6K1. It is proposed to be present in the nuclei of human normal fibroblasts (Rosner & Hengstschläger, 2011) . Overall, S6K1 subcellular localization data have been based predominantly on subcellular fractionation assay or immunocytochemical analysis of recombinantly expressed proteins. However, information about the nucleocytoplasmic distribution of the endogenous S6K1 is still limited, and mechanisms of its regulation remain elusive.
Recent studies suggest that S6K1 subcellular localization and activation may also depend on the physiological status of different tissues. Immunohistochemical analysis of malignant breast tumors revealed prominent S6K1 accumulation in the nuclei of carcinoma cells (Filonenko, 2013; Filonenko et al., 2004; Lyzogubov et al., 2005) . In other studies, it was shown that nuclear accumulation of S6K1 correlated with the reduced tamoxifen effect in breast cancer patients, while cytoplasmic localization of S6K1 was associated with better prognosis for the patients (Bostner et al., 2015) .
Migration of the cancer cells is an important stage of cancer progression, leading the tumor invasion and formation of distant metastases. The recent data suggest that S6K1 may be involved in the regulation of the motility of normal and malignant cells, as knockdown of p70S6K1 or inhibition of S6K1 kinase activity caused a significant decrease in the migration speed of the prostate, breast, and ovarian cancer cells in vitro (Amaral et al., 2016; Ip et al., 2011) . Moreover, activation of p70S6K1 in human ovarian carcinoma cells in response to stimulation by hepatocyte growth factor (HGF) also led to increased expression of matrix metalloproteinase 9 (MMP9) and higher migration rate of these cells (Zhou & Wong, 2006) . It was shown that active p70S6K1 could also induce activation of Cdc42, Rac1, and PAK1 -the known regulators of cell migration through actin cytoskeleton remodelling (Aslan et al., 2011; Liu et al., 2010) . Besides, S6K1 was also found to colocalize with the actin arches at the leading edge of moving mesothelioma cells. Treatment with rapamycin (specific mTOR inhibitor) reduced the formation of actin arches even when cells were stimulated with epithelial growth factor (EGF) (Berven et al., 2004; Liu et al., 2008) . However, the link between subcellular localization of S6K1 and its functions in migrating cancer cells is not fully yet understood.
In the present research, we focused on the study of subcellular localization of endogenous S6K1 in breast tumor and normal tissue, and in breast adenocarcinoma MCF-7 cells in monolayer culture, 3D multicellular spheroids, and in the course of
Introduction
Ribosomal protein S6 kinase 1 (S6K1) belongs to the AGC family of serine/threonine protein kinases (Ruvinsky & Meyuhas, 2006) . It is involved in the regulation of crucial physiological processes, such as protein synthesis, ribosomal biogenesis, the G1/S-phase cell cycle transition, mRNA splicing, differentiation of specific cell types, and apoptosis. The large number of intracellular targets makes S6K1 a key regulator of cell size, growth, and proliferation (Magnuson et al., 2012) . S6K1 activity is controlled by the PI3K/Akt/mTOR signaling pathway, which has been shown to be dysregulated in diverse human pathologies, including diabetes, obesity, neurodegenerative disorders, and cancer (Tavares et al., 2015) . Overexpression of S6K1 was found in several tumor types, including breast cancer, and was associated with the worse disease outcome for the patients (Bostner et al., 2015) .
In mammalian cells, S6K1 is encoded by RPS6KB1 gene located at the chromosome 17. Several isoforms of the S6K1 protein are known: the 85kDa S6K1 and the 70kDa S6K1 (p85S6K1 and p70S6K1 respectively), which originate from alternative translation initiation sites, and hypothetical p60S6K1, which is also suggested to be a product of alternate mRNA translation (Kim et al., 2009) . Recently, the new 31kDa isoform of S6K1 (p31S6K1) encoded by mRNA splice variant was also identified. Although it has been shown that p31S6K1 protein lacks the catalytic activity of the kinase domain, it still possesses oncogenic properties (Ben-Hur et al., 2013; Song & Richard, 2015) . The longer isoform p85S6K1 has an additional 23 amino acid extension at the N-terminus of the molecule functioning as a nuclear localization signal. In early studies p85S6K1 was induced cancer cell migration. We found that nucleocytoplasmic distribution of S6K1 depends greatly on the density of the monolayer culture, and is different between the cells in 3D vs 2D culture conditions. Moreover, we found that S6K1 is relocalized to the nucleus during migration of MCF-7 cells from multicellular spheroids onto growth surface. In addition, we analyzed the possible interaction of S6K1 with a number of transcription factors, involved in the regulation of cell motility. For the first time, we described the interaction of S6K1 and TBR2 (T-box brain protein 2) in breast cancer cell line MCF-7. Together, these data suggest that during cell migration S6K1 interacts with the transcription factors in the cell nucleus, leading to the possibility of its transcriptional regulation of the genes that are involved in the control of cellular locomotor activity.
Methods
Cell culture
Human breast adenocarcinoma cell line MCF-7 was obtained from Bank of Cell Lines of the R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU (Ukraine). The cells were cultivated in DMEM culture medium (Gibco, USA) supplemented with 10% fetal calf serum (FCS, HyClone, USA), 4 mM glutamine, 50 units/ml penicillin, 50 µg/ml streptomycin at 37°C in presence of 5% CO 2 . The medium was exchanged every third day. For immunofluorescence analysis cells were seeded onto sterile glass coverslips 48 hours before the experiments.
To form multicellular spheroids, MCF-7 cells were trypsinized, and 1×10 6 cells were seeded into 100 mm Petri dishes, that were previously coated with 1% agarose (Sigma-Aldrich, A9045), and left to form the multicellular aggregates for the additional 72 h.
For the induction of spheroid-to-monolayer transition and cell migration, multicellular spheroids were transferred onto growth surface (glass coverslip) and further cultured for 24 to 72 h. Then outspreaded spheroids were fixed and used for immunofluorescence analysis.
Cellular and spheroid morphology was also evaluated using transmitted light microscopy (CETI Versus inverted microscope, CETI, Belgium, and Leica DM 1000, Leica Microsystems, Germany).
Immunofluorescence analysis MCF-7 cells were fixed with 10% formalin for 15 min at room temperature (RT). After this, the cells were permeabilized with 0.2% Triton X-100 in PBS for 10 min. To reduce autofluorescence, the samples were incubated with 10 mM cupric sulphate and 50 mM ammonium acetate, pH 5.0 for 30 min at RT. Non-specific binding was blocked through the incubation with 10% FCS in PBS for 30 min at 37°C in a humidified chamber.
S6K1 subcellular localization was revealed using anti-S6K1-Cterminus rabbit polyclonal antibodies (generated and evaluated earlier (Savinska et al., 2001 ; if you are interested in obtaining this antibody, please contact the corresponding author)) at 1:100, and anti-phospho-S6K1 (T389) rabbit polyclonal antibodies at 1:20 (Cell Signaling Technology Cat# 9205, RRID:AB_330944). The secondary Fluorescein (FITC)-AffiniPure Goat Anti-Rabbit IgG (H+L) antibody 1:400 (Jackson ImmunoResearch Labs Cat# 111-095-003, RRID:AB_2337972) were applied for 45 min at 37°C in a humidified chamber. Double immunofluorescence analysis was performed by addition of the primary antibody mix: anti-S6K1-C-terminal mouse monoclonal antibodies (generated earlier (Pogrebnoy et al., 1999) ; if you are interested in obtaining this antibody, please contact the corresponding author) at 1:100 + anti-TBR2 rabbit polyclonal antibodies at 1:100 (Abcam Cat# ab23345, RRID:AB_778267) overnight at +4°C in a humidifyied chamber. The secondary Fluorescein (FITC)-AffiniPure Donkey Anti Mouse IgG (H+L) antibody (Jackson ImmunoResearch Labs Cat# 715-095-150, RRID:AB_2340792) at 1:400, and Rhodamine (TRITC)-AffiniPure Donkey Anti-Rabbit IgG (H+L) antibody (Jackson ImmunoResearch Labs Cat# 711-025-152, RRID:AB_2340588) at 1:400 were applied for 45 min at 37°C in a humidifying chamber. Samples were embedded into Mowiol medium (Sigma-Aldrich, USA) containing 2.5% DABCO (Sigma-Aldrich), 0.5 % DAPI (Sigma-Aldrich).
Microscopy image acquisition was performed using Leica DM 1000 epifluorescent microscope and Zeiss LSM 510 META point scanning confocal microscope (Carl Zeiss Microscopy GmbH, Germany). Fluorescence images were analyzed using Fiji/ImageJ v1.52b (Fiji, RRID:SCR_002285; Schindelin et al., 2012) . Figures were generated with the FigureJ plugin (Mutterer & Zinck, 2013) in Fiji/ImageJ v1.52b.
For quantitative characterization of colocalization Pearson coefficient and Manders coefficients (M1 and M2) analysis was performed on the background-subtracted images using JACoP plugin (Bolte & Cordelières, 2006) in Fiji/ImageJ v1.52b. Pearson coefficient (Rr) and Manders coefficients (M1 and M2) were expressed as mean value +/-SD, the experiments were performed in duplicates. To validate and describe the obtained degree of colocalization pre-defined image sets from Colocalization Benchmark Source were used. Obtained values of the colocalization coefficients were used to find the closest benchmark.
Immunohistochemical analysis
Histological samples of human mixed ductal/lobular carcinoma of the breast and surrounding conditionally normal tissue were obtained from 10 patients within the framework of the cooperation agreement between the National Cancer Institute and the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine. This study has been approved by the Committee on Biological & Medical Ethics of the National Cancer Institute of Ukraine (approval number -№ 67, 25.03.2015). Written informed consent was obtained from all patients for the use of their tissues in research.
Sections of human breast cancer and surrounding tissues or multicellular spheroids were deparaffinized in xylene and rehydrated in a series of graded alcohol solutions. For the antigen retrieval, slides were placed in citrate buffer (10 mM citric acid, pH 6.0) and subsequently boiled two times for 5-7 min. Then, sections were treated with 0.2% Triton X-100 for 10min. Endogenous peroxidase was quenched by incubation of the samples with the 3% H 2 O 2 in PBS for 30 min. After blocking of non-specific staining with 10% FCS in PBS, sections were incubated with anti-S6K1-C-terminal rabbit polyclonal antibodies (1:100) overnight at +4°C, and next with the peroxidase-conjugated secondary antibodies (1:100; Promega Cat# W4011, RRID:AB_430833) for 1 hour at 37°C. The reaction was developed with 3,3'diaminobenzidine (Sigma-Aldrich) solution.
Bioinformatic analysis
Prediction of potential TBR2 phosphorylation sites by S6K1 was performed using Group-based Prediction System v2.1 (Xue et al., 2011; GPS, RRID:SCR_016374) . The sequence of human TBR2 was obtained from the National Center for Biotechnology Information, NCBI Reference Sequence: NP_ 001265111.1.
Immunoprecipitation and immunoblot analysis
Anti-S6K1 mouse monoclonal antibodies (Pogrebnoy et al., 1999) were immobilized on protein A/G PLUS Agarose beads (Santa Cruz Biotechnology) overnight at +4 C.
MCF-7 cells were washed with ice-cold PBS and extracted with lysis buffer, containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 50 mM sodium fluoride, 5 mM β-glycerophosphate,10 mM sodium pyrophosphate, 1 mM sodium orthovanadate and a mixture of protease inhibitors (Roche Molecular Diagnostics, France). Cell lysates were centrifuged at 13 000 rpm for 20 min at 4°C. Endogenous S6K1 was precipitated by adding 1000µg of total cell lysates to the immobilized antibodies and incubating overnight at 4°C. Immune complexes were washed three times with lysis buffer, boiled for 5 min in Laemmli sample buffer, and used for immunoblot analysis. As a control, protein A/G PLUS Agarose beads were incubated with monoclonal antibodies or cell lysates alone.
For the western blot analysis, obtained samples were separated by 10% SDS-PAGE and transferred onto PVDF membrane (Millipore, Billerica, MA). The non-specific binding was blocked with 5% skim milk in PBST (140 mM NaCl, 2.6 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , 0,05% Tween-20, pH 7.4) for 1 h at RT, and then incubated with anti-TBR2/Eomes rabbit antibodies at 1:500 (Abcam Cat# ab23345, RRID:AB_778267) or anti-S6K1 C-terminal rabbit polyclonal antibodies 1:3000 overnight at 4°C. After washing three times with PBST, HRPconjugated goat anti-rabbit IgG (Jackson ImmunoResearch Labs Cat# 111-035-144, RRID:AB_2307391) in 1:10 000 dilution were incubated with the membrane for 1 h at RT. The signal was developed using an enhanced chemiluminescence system (Fluco) and then exposed to Agfa X-ray film.
Results and discussion
Immunochemical detection of S6K1 subcellular localization in human breast cancer cells Firstly, the subcellular distribution of S6K1 was determined in the histological sections of human breast cancer and normal tissues. As in previous studies, we also observed the preferential nuclear localization of S6K1 in the malignant breast cells (Bostner et al., 2015; Filonenko et al., 2004) and mainly cytoplasmic one in conditionally normal adjustment tissues ( Figure 1A, B) .
In recent years, the 3D cell culture systems have been shown to provide numerous advantages to study tumor growth in a more physiologically relevant environment (Bingel et al., 2017) . This motivated us to further compare the intracellular distribution of S6K1 in MCF7 cells grown as either multicellular spheroids or a conventional monolayer cell culture. In the multicellular spheroids of MCF7 cells, we detected a strong accumulation of S6K1 in the cytoplasm and its reduction in the nuclei ( Figure 1C ). In contrast to this, in the 40-60% confluent monolayer of MCF7 cells S6K1 was localized mostly to the nucleus, with the moderate signal in the cytoplasm of the same cells ( Figure 1D ).
Nucleocytoplasmic redistribution of S6K1 in MCF-7 cells at different cell density A significant difference in S6K1 localization in monolayer and spheroid cultures can be caused by differences in cell growth conditions in two different types of culture. Such differences could be potentially caused by a cascade of intracellular signaling events induced by cell-matrix adhesion or intercellular interactions. One may assume that the S6K1 could be involved in such intracellular rearrangement. To clarify this, we analyzed the S6K1 subcellular localization in MCF-7 cells cultured at different densities. The immunofluorescence analysis revealed the changes of S6K1 localization from the nucleus to the cytoplasm correlating with increased cell culture density (Figure 2A-E) . At the lowest cell density level, S6K1 was observed predominantly in the nuclei of cultured cells whereas at the highest cell density S6K1 was concentrated in the cytoplasm.
In order to further asses the possible connection between the subcellular localization of S6K1 and the cell density, we utilized the following approach. After reaching approximately 90% of confluence, the monolayer of MCF-7 cells was gently detached from growth surface by short treatment with trypsin (w/o EDTA), and placed in fresh culture medium. Subsequent cultivation of these monolayer fragments for additional 48 h led to still high cell density in the center of fragments and decreased density of cells at the edges of the fragments. Immunofluorescence analysis of this heterogenous population of the cells revealed that cell spreading at the edges of the dense fragments was accompanied by the alterations in S6K1 localization from predominantly cytoplasmic to nuclear ( Figure 2F ). 
Subcellular localization of S6K1 in migrating MCF-7 cells
Obtained data led to the hypothesis that there is a possible relation between the initiation of cell migration and the relocalization of S6K1. Among the variety of cell migration models, the approaches based on the 3D cell cultures are the ones that provide several unique advantages for studying tumor cell migration and invasion (Metzger et al., 2017) . As mentioned previously, many studies describe the structural and physiological similarity of multicellular spheroid organization to the structure of solid malignant tumors (Rodrigues et al., 2018) . Also, the transformation of 3D multicellular spheroids into the 2D cell colonies upon contact with adhesive surface can be realized only through cell migration, in contrast to the monolayer migration assays, where cell proliferation also plays a role. Therefore, spheroid to monolayer reversion model to assess the nucleocytoplasmic distribution of S6K1 was utilized (Figure 3) . We applied the immunofluorescence analysis of cultured cells 24 and 72 hours after initiation of the MCF7 spheroid migration. Obtained data suggested that there is a significant relocalization of S6K1 from the cytoplasm into the nuclei in course of cell migration ( Figure 4A, B) . The cells, remaining within the spheroid retained the positive cytoplasmic and negative nucleic reaction for S6K1, similar to the cells of spheroid at histological sections regardless of their remoteness from the edge of the spheroid ( Figure 1C ), while the migrating cells at the edge of the spreading spheroid demonstrated strong accumulation of S6K1 in the nuclei ( Figure 4B ). The mTOR dependent Thr389 phosphorylation of S6K1 is the most frequently used marker for the S6K1 activity (Romanelli et al., 2002) . Therefore, we analyzed the phosphorylation status of S6K1 in MCF-7 cells during spheroid transformation into monolayer by immunofluorescence analysis. Overall, the pattern of phospho-S6K1 distribution was similar to that observed for total S6K1 ( Figure 5 ). In particular, in the central part of the spheroid, S6K1 was mainly observed in the cytoplasm (however some of the nuclei were positive), whereas the cells at the leading edge of spheroid demonstrated predominant nuclear localization of phospho-S6K1 ( Figure 5A ). Also, strong nuclear localization of phospho-S6K1 (Thr389) was revealed in monolayer culture of MCF-7 cells ( Figure 5B ). S6K1 function in nuclei and cell migration While our data suggested that activation of cell locomotor function is accompanied by cytoplasm/nuclear shuttling of S6K1, the biological meaning of the event was not clear. One of the possible explanations could be the implication of S6K1 in the regulation of transcription factors affecting expression of genes that control cell migration.
That's why, we analyzed the subcellular distribution of several transcription factors, which are known to be regulated by the mTOR/S6K signaling pathway and activated in migrating cells either in the cancer tissues or in the process of embryonic development. One of them is the mammalian transcription factor CDX2, which plays a key role in intestinal development and differentiation. It has been previously described that reduced expression of CDX2 may contribute to the colon tumorigenesis through involvement in the mTOR-mediated chromosomal instability (Aoki et al., 2003) . Fusion of another transcription factor ERG and androgen-responsive TMPRSS2 serine protease has been shown to contribute to the development of the prostate cancer. There is also a strong correlation between TMPRSS2-ERG fusion and activation of mTOR/S6K pathway (Faraj et al., 2013; King et al., 2009) . The third transcription factor chosen for this study was T-box transcription activator Eomesodermin (or TBR2) (Conlon et al., 2001 ), which was also described as one of the targets for anticancer therapy. It has been shown that siRNA knockdown of Eomesodermin in human hepatocellular carcinoma could significantly decrease anchorage-independent cell growth (Gao et al., 2014) . Besides this, TBR2 has also been shown to be involved in the process of lymphocyte differentiation. The mTOR-dependent regulation of expression of transcription factors T-bet and Eomesodermin has been shown to be heavily involved in the determination of effector of memory cell fates in CD8+ T cells (Cui et al., 2016) .
Our immunofluorescence analysis of subcellular distribution of S6K1 and mentioned transcription factors in MCF-7 cells revealed that ERG was present in scant quantities or not determined at all in MCF-7 cells (Dataset 4; (Kosach et al., 2018d) ). CDX2 staining led to identification of positive dots predominantly in the nuclei of the MCF7 cells, however, CDX-2 and S6K1 colocalization was not detectable by confocal microscopy (Dataset 4; (Kosach et al., 2018d) ). TBR2/Eomesodermin positive speckles were observed in the cytoplasm as well as in nuclei of the cells (Figure 6A, B) . In both cases, partial but intense colocalization of TBR2 and S6K1 was detected. Moreover, in the low-density monolayer, when S6K1 localized mainly in the cell nuclei, TBR2 was observed predominantly in the nuclei as well. In the high-density monolayer cultures, where S6K1 was distributed in the cell cytoplasm, TBR2 also displayed a similar pattern of intracellular distribution ( Figure 6A, B) . For quantitative characterization of S6K1 and TBR2 colocalization, Pearson coefficient (Rr) and Manders coefficient (M1 and M2) analysis was performed on background-subtracted images using JACoP ImageJ plugin (Bolte & Cordelières, 2006) . M1 shown the colocalization of S6K1 with TBR2, whereas M2 expressed the pool of TBR2 colocalizing with S6K1. Colocalization analysis of S6K1 and TBR2 in low density monolayer revealed Pearson coefficient Rr= 0.55 +/-0.113, M1= 0.999 +/-0.01, M2= 0.84 +/-0.087. To validate and describe the obtained degree of colocalization pre-defined image sets from Colocalization Benchmark Source were used. The closest benchmark was CBS007RGM that corresponded to 60% colocalization, thus indicating the medium level of colocalization between TBR2 and S6K1. A slightly lower but reliable colocalization of S6K1 and TBR2 was observed in a monolayer with a high density. Namely Pearson coefficient was Rr=0.47 +/-0.064, Manders coefficients were M1=0.995 +/-0.004 and M2=0.62+/-0.187. So, a slightly higher level of S6K1 and TBR2 colocalization was revealed in MCF-7 cells grown in low density monolayer, when S6K1 and TBR2 localized mainly in the nuclei.
Further immunoprecipitation experiments also confirmed the physical interaction of S6K1 and TBR2 (Figure 7) . Protein complexes containing S6K1 were extracted from cultured MCF-7 cell lysate using anti-S6K1 antibodies and then blotted with antibodies to TBR2. Obtained results revealed the protein complex formation of S6K1 and TBR2, leading to the hypothesis of the possibility of TBR2 regulation via S6K1 mediated phosphorylation.
Dataset 5. Unedited western blot images of coimmunoprecipitation of S6K1 and TBR2 used in Figure 7 https://dx.doi.org/10.5256/f1000research.15447.d214434
To assess this possibility of S6K1-mediated TBR2 phosphorylation, we performed a computational prediction of phosphorylation sites in TBR2 (GPS 2.1), which indicated several potential phosphorylation sites, and three of them (Thr421, Thr423, Ser646) could be phosphorylated by S6K1 with a high probability score (Figure 8 ). Interestingly, both Thr421 and Thr423 were located in the DNA binding domain indicating that their phosphorylation could be related to the binding affinity of this transcription factor to the DNA. Another phosphorylation site (Ser646) was located within transcription activation domain at C-terminus of TBR2, which is thought to be involved in transcription activation. Taken together, this data suggests that S6K1 can be involved in the regulation of TBR2 transcription activity. However, further research is needed to confirm if S6K1 phosphorylates TBR2 in vitro and in vivo.
In the course of embryonic and postnatal development, Eomesodermin has been shown to induce the expression of a large Group-based Prediction System v2.1 was used for bioinformatics analysis. It revealed that TBR2 contained three sites that could be phosphorylated by S6K1 with a high probability (A). Two of them, Thr421 and Thr423, are located in the DNA binding domain of the TBR2. Third site Ser646 is located within the transcription activation domain at C-terminus of TBR2 (B). spectrum of mesodermal genes in all types of mesodermal cells, which could also be expressed in malignant cells of nonmesodermal origin (Reim et al., 2017; Russ et al., 2000) .
Considering the multiplicity of S6K1 substrates, possible phosphorylation of the TBR2 transcription factor is not the only reason for the movement of the kinase from the cytoplasm into the nucleus of migrating cells. However, the proposed interaction can partially explain the accumulation of kinase in the nucleus of moving cells. In addition to the previously known classical nuclear substrates of S6K1, in case of breast cancer, it is necessary to note that this kinase can activate estrogen receptor-α, which is a nuclear transcription factor by its phosphorylation at Ser167 in a ligand-independent manner (Yamnik & Holz, 2010) . Besides, recent data indicate that S6K1 is targeted by histone acetyltransferases p300 and p300/CBP-associated factor (PCAF). The significance of this acetylation is not fully clear, but by analogy with S6K2, it is assumed that S6K1 is involved in the regulation of the transcription process (Fenton et al., 2010) . Summing up, there are a number of data confirming the nuclear localization of S6K1, but the role that S6K1 performs in the nucleus of migrating malignant cells require further investigation.
Conclusions
For the first time, this study revealed the interconnection between MCF-7 cell density and S6K1 subcellular distribution: nuclear localization of the kinase was observed at low density monolayer, while in the confluent monolayer S6K1 was detected predominantly in the cytoplasm. Besides, S6K1 nucleocytoplasmic relocalization was revealed in migrating MCF-7 cells using spheroid-to-monolayer reversion model.
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At the end of the fourth paragraph of the Introduction, the authors refer to EGF as "endothelial growth factor". This should be corrected to "epithelial growth factor". The value of the first paragraph of the Results section (There are several... of different function.") is not clear and should be deleted. On Page 13 of the manuscript, the authors refer to 2 residues on TRB2, Tyr421 and Tyr423, as potential sites phosphorylated by S6K1. S6K2 is a Ser/Thr kinase and therefore unable to phosphorylate Tyr residues. Are the authors referring to Thr sites instead? Please clarify. The authors argue that interaction of S6K1 with TRB2 may be involved in the migration of cells out of microspheres onto 2D layers. This is an interesting proposition and the manuscript would benefit from an experiment being performed using siRNAs to TRB2 and showing that this impacts either S6K1 distribution or the movement of cells out of the microspheres. The style of the paper is poor in places and could be improved prior to indexing.
1.
one from the possible reasons of S6K1 subcellular redistribution in course of MCF-7 cell migration. The level of their colocalization is statistically significant, but not very high, so, under TBR2 down-regulation we can obtain partial alteration of S6K1 relocalization that will be difficult to assay. Therefore, in the present work, we so far only point to the revealed colocalization. And we hope to develop this area of research in future.
The style of the paper is poor in places and could be improved prior to indexing. The manuscript was proofread by a person with advanced level of scientific English. We believe that this greatly improved the style of the text.
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